Summary
In a significant market movement during November 2023, ViaNautis was the subject of a vc funding. The transaction achieved a gross valuation of £20,000,000. Leading the round was 4BIO Capital, UCB Ventures, o2h Ventures, Origin Capital, BGF, Meltwind, Eli lilly and company, Cystic Fibrosis Foundation.
This transaction was brokered by an undisclosed advisor. The deal reflects ongoing market confidence within its sector.
Lead Investor / Acquirer
4BIO Capital
Lead Investor / Acquirer
UCB Ventures
Lead Investor / Acquirer
o2h Ventures
Lead Investor / Acquirer
Origin Capital
Lead Investor / Acquirer
BGF
Lead Investor / Acquirer
Meltwind
Lead Investor / Acquirer
Eli lilly
Lead Investor / Acquirer
company
Lead Investor / Acquirer
Cystic Fibrosis Foundation
Advising Broker
Undisclosed Firm
Related Deals in Healthcare & Biotech
Series A prioritisedOriginal Source
This funding round is sourced from the Tech.eu Funding Explorer. View the full record, investors, and citations there.
View on Tech.eu Funding ExplorerFunding data via Tech.eu Funding Explorer, licensed under CC BY 4.0. See our methodology.
AI Insight Lenses
ProAI-generated analysis from four professional perspectives. Powered by PE Deals.
Sign in to unlock AI Lenses
Sign in